Newron Pharmaceuticals - Long-term generic challenge to Xadago
The FDA has notified Newron that an application for a generic safinamide (Xadago) has been filed. Xadago has new chemical entity (NCE) exclusivity...
408 Views
Newron Pharmaceuticals - Evenamide trial progressing well
Newron has reported excellent, fast recruitment for the Phase II study of its novel schizophrenia drug, Evenamide, due to report in Q121. Newron...
97 Views
Newron Pharmaceuticals - Evenamide safety trial underway
Newron is focusing on its novel schizophrenia drug, Evenamide, and on a further Xadago study. The Evenamide preclinical studies required by the FDA...
92 Views
Newron Pharmaceuticals - Evenamide focus, Supernus to sell Xadago in US
Given that sarizotan did not meet the primary or any secondary endpoints in the pivotal Rett syndrome STARS study, Newron is focusing on its novel...
50 Views
Newron Pharmaceuticals - Sarizotan fails to shine
On 4 May Newron Pharmaceuticals announced that the pivotal Rett syndrome STARS study of sarizotan had not met the primary or any secondary...
100 Views